DR. KEITH EUGENE FRIEND, M.D.
Osteopathic Medicine at Everitts Hill Rd, Flemington, NJ
License number
New Jersey 25MA07426800
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
39 Everitts Hill Rd, Flemington, NJ 08822
Phone
(908) 894-0192
Personal information
See more information about KEITH EUGENE FRIEND at radaris.comName
Address
Phone
4 Forest View Dr, Gladstone, NJ 07934
39 Everitts Hill Rd, Flemington, NJ 08822
288 Washington Ave, Westwood, NJ 07675
17 Seville Pl, Toms River, NJ 08757
4 Forest View Dr, Gladstone, NJ 07934
Professional information
Dr. Keith E Friend, Gladstone NJ - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism
Address:
4 Forest View Dr, Gladstone 07934
39 Everitts Hill Rd, Flemington 08822
(908) 894-0192 (Phone)
39 Everitts Hill Rd, Flemington 08822
(908) 894-0192 (Phone)
Certifications:
Diabetes, Metabolism & Endocrinology, 1991, Internal Medicine, 1989
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Maryland At Baltimore / Professional Schools
Graduated: 1986
Mercy Medical Center
U Va Hlth Scis Ctr
University of Maryland At Baltimore / Professional Schools
Graduated: 1986
Mercy Medical Center
U Va Hlth Scis Ctr
Methods And Compositions For Treating, Preventing Or Delaying Onset Of A Neoplasm
US Patent:
2003021, Nov 13, 2003
Filed:
Apr 25, 2003
Appl. No.:
10/423761
Inventors:
Keith Friend - Flemington NJ, US
International Classification:
A61K031/4745
US Classification:
514/283000
Abstract:
Methods of treating, preventing or delaying onset of a neoplasm comprise administering to an individual an anti-neoplastic agent and a growth hormone receptor antagonist. Methods for reducing tumor weight or volume comprise administering to an individual an anti-neoplastic agent and a growth hormone receptor antagonist. Compositions comprise an anti-neoplastic agent and a growth hormone receptor antagonist.
Therapeutical Conversion
US Patent:
2005015, Jul 14, 2005
Filed:
May 6, 2004
Appl. No.:
10/840025
Inventors:
Pia Burman - Uppsala, SE
Keith Friend - Flemington NJ, US
Keith Friend - Flemington NJ, US
International Classification:
A61K038/08
US Classification:
514016000
Abstract:
This invention provides a method of therapeutical conversion from a long-acting release (LAR) formulation of octreotide, e.g. Sandostatin® LAR®, to pegvisomant (Somavert®) for the acromegalic patients through a therapeutically overlapping transition period to a final dose range of pegvisomant established.